Source: Netherlands Cancer Institute Tumor fragments in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. “We’ve solved a major problem many scientists had been facing: preserving a tumors original composition and structure outside of the patient in the lab”, says cancer researcher Daniela Thommen from the Netherlands Cancer Institute. On 8 July, the …
Natural killers: Using the body’s cells to target breast cancer
Source: Clemson Universitty From: medicalxpress.com It sounds like a plot from a Quentin Tarantino movie—something sets off natural killers and sends them on a killing spree. But instead of characters in a movie, these natural killers are part of the human immune system and their targets are breast cancer tumor cells. The triggers are fusion proteins developed by Clemson University …
Triple-Negative Breast Cancer Treatments Continue to Evolve
By: HAYLEY VIRGIL From: oncnursingnews.com Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and eliciting impressive response rates in heavily pretreated patients. “There are some exciting new therapies for the treatment …
Clinical trials are vital for battling breast cancer
From: local10.com In the battle against breast cancer, researchers and patients are teaming up to uncover new treatment options. When Debora Pedrini was diagnosed with early-stage triple-negative breast cancer in 2019 she didn’t expect to become part of a clinical trial. “When the clinical trial was offered to me, to be honest with you, it was a hurricane of feelings. …
Immunotherapy Drug Development Pipeline Continues Significant Growth In 2020 Despite Global Pandemic Impact
From: cancerresearch.org Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them. The volume of clinical investigations testing I-O therapies for the treatment of cancer continues to grow with hundreds of new cell therapies being added …
An Expert Explains the Three Major Treatment Modalities in Triple Negative Breast Cancer
By: Jessica Skarzynski From: curetoday.com “In the field of triple-negative breast cancer, we’re beginning to see some remarkable advances, mostly centering around the three paradigms that have become so attractive for the treatment of cancer: immunotherapy, targeted biologics and antibody-drug conjugates,” Dr. Howard A. “Skip” Burris, III said in an interview. When it comes to treating triple-negative breast cancer (TNBC), …
Research uncovers clues in use of immunotherapy for breast cancer
By: University of Cincinnati From: medicalxpress.com UC researchers have found a potential new combination therapy for breast cancer that would integrate use of the body’s immune system with targeted treatment for a particular protein that advances cancer. The study, published in the journal Cancer Research, a journal of the American Association for Cancer Research, provides data that could eventually lead …
A boost for cancer immunotherapy
By: Anne Trafton | MIT News Office From: mit.edu Engineers design nanoparticles that stimulate the immune system, helping it to attack tumors. One promising strategy to treat cancer is stimulating the body’s own immune system to attack tumors. However, tumors are very good at suppressing the immune system, so these types of treatments don’t work for all patients. MIT engineers …
First Trial of Immunotherapy in Early-Stage Triple-Negative Breast Cancer Shows Promising Results
By: Danielle Ternyila From: targetedonc.com In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the findings from the interim analysis for the phase III KEYNOTE-522 study, which added pembrolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer. The randomized, phase III KEYNOTE-522 clinical trial evaluated the benefit of adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to …
Immunotherapy improves outcome in high-risk, HER2-negative breast cancer
By: Megan Brooks From: reuters.com Adding the immune-checkpoint inhibitor durvalumab and the PARP inhibitor olaparib to standard neoadjuvant chemotherapy may improve outcome in women with high-risk, HER2-negative breast cancer, according to results of the I-SPY 2 trial. The benefit was apparent in both the hormone-receptor-positive (HR+) and triple-negative breast cancer (TNBC) subgroups. The I-SPY 2 study enrolled women with high-risk, …